PDF(Pubmed)
Abstract：
UNASSIGNED: To systematically summarise the current clinical evidence for de novo malignant upper urinary tract obstruction treatment with a focus on standards of reporting, patient outcomes and future research needs.
UNASSIGNED: This review protocol was published via PROSPERO (CRD42022341588). OVID MEDLINE (R), EMBASE, Cochrane Central Register of Controlled Trials-CENTRAL were searched up to June 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses. Prospective and retrospective studies were included.
UNASSIGNED: Of 941 articles identified, 82 with 8796 patients were eligible for inclusion.Most studies in the published literature are retrospective and investigate heterogenous malignancies. Percutaneous nephrostomy and ureteric stenting are the most studied interventions. Few studies describe the outcomes from no intervention or investigate patient perspectives. Overall reported median survival after intervention was around 11.7 months. A lack of standardised reporting of outcomes was evident.
UNASSIGNED: Malignant upper urinary tract obstruction is an important clinical condition affecting patients globally. Overall survival after intervention appears poor however the current evidence base has significant limitations due to studies of low methodological quality and the lack of a standardised framework for reporting outcomes.We have provided a pragmatic framework for future studies based on the review to ensure a uniform methodology is utilised moving forward.
UNASSIGNED: This review protocol was published via PROSPERO (CRD42022341588). OVID MEDLINE (R), EMBASE, Cochrane Central Register of Controlled Trials-CENTRAL were searched up to June 2022 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses. Prospective and retrospective studies were included.
UNASSIGNED: Of 941 articles identified, 82 with 8796 patients were eligible for inclusion.Most studies in the published literature are retrospective and investigate heterogenous malignancies. Percutaneous nephrostomy and ureteric stenting are the most studied interventions. Few studies describe the outcomes from no intervention or investigate patient perspectives. Overall reported median survival after intervention was around 11.7 months. A lack of standardised reporting of outcomes was evident.
UNASSIGNED: Malignant upper urinary tract obstruction is an important clinical condition affecting patients globally. Overall survival after intervention appears poor however the current evidence base has significant limitations due to studies of low methodological quality and the lack of a standardised framework for reporting outcomes.We have provided a pragmatic framework for future studies based on the review to ensure a uniform methodology is utilised moving forward.
摘要：
■为了系统地总结新发恶性上尿路梗阻治疗的当前临床证据，重点是报告标准，患者预后和未来研究需求。
■本综述方案通过PROSPERO(CRD42022341588)发布。OVIDMEDLINE（R），EMBASE,截至2022年6月，根据系统评价和荟萃分析的首选报告项目搜索Cochrane中央对照试验登记册CENTRAL。纳入前瞻性和回顾性研究。
■在确定的941篇文章中，82例，8796例患者符合纳入条件。已发表文献中的大多数研究都是回顾性的，并研究了异质性恶性肿瘤。经皮肾造口术和输尿管支架置入术是研究最多的干预措施。很少有研究描述没有干预或调查患者观点的结果。总体报告的干预后中位生存期约为11.7个月。结果缺乏标准化报告是显而易见的。
■恶性上尿路梗阻是影响全球患者的重要临床病症。干预后的总体生存率似乎很差，但是由于方法学质量低和缺乏报告结果的标准化框架，目前的证据基础存在很大的局限性。我们为基于审查的未来研究提供了一个务实的框架，以确保使用统一的方法向前发展。
■本综述方案通过PROSPERO(CRD42022341588)发布。OVIDMEDLINE（R），EMBASE,截至2022年6月，根据系统评价和荟萃分析的首选报告项目搜索Cochrane中央对照试验登记册CENTRAL。纳入前瞻性和回顾性研究。
■在确定的941篇文章中，82例，8796例患者符合纳入条件。已发表文献中的大多数研究都是回顾性的，并研究了异质性恶性肿瘤。经皮肾造口术和输尿管支架置入术是研究最多的干预措施。很少有研究描述没有干预或调查患者观点的结果。总体报告的干预后中位生存期约为11.7个月。结果缺乏标准化报告是显而易见的。
■恶性上尿路梗阻是影响全球患者的重要临床病症。干预后的总体生存率似乎很差，但是由于方法学质量低和缺乏报告结果的标准化框架，目前的证据基础存在很大的局限性。我们为基于审查的未来研究提供了一个务实的框架，以确保使用统一的方法向前发展。
